Effects of Tanshinone Combined with Western Medicine on Clinical Symptoms and Cardiac Function in Patients with Acute Heart Failure

OBJECTIVE: To explore the effects of Tanshinone combined with western medicine on clinical symptoms and cardiac function in patients with acute heart failure. METHODS: The medical records of 96 patients with acute heart failure were randomly divided into 2 groups(48 cases in observation group and 48 cases in control group). The control group was treated with conventional western medicine, and the observation group was treated with Tanshinone IIA sulfonic acid natrium on the basis of western medicine. The traditional Chinese medicine(TCM) syndromes scores before and after treatment(after 28 d of treatment), clinical efficacy, and cardiac echocardiographic indexes and serum biochemical indicators before and after treatment were observed in the 2 groups. RESULTS: After treatment, the scores of TCM syndromes in the 2 groups were significantly decreased(P < 0.05), and the change in observation group was significantly greater than that in control group(P < 0.05). The total clinical effective rate in observation group was significantly higher than that in control group(91.67% vs 75.00%)(P < 0.05). After treatment, the echocardiographic indexes of left ventricular end-diastolic diameter(LVEDD) and left ventricular end-systolic diameter(LVESD) values were significantly reduced in the 2 groups while the left ventricular ejection fraction(LVEF) and stroke volume(SV) value were significantly increased, and the changes in observation group were significantly larger than those in control group(P < 0.05). After treatment, the levels of serum nuclear factor-kappaB(NF-KB), interleukin-1β(IL-1β) and N-terminal pro-brain natriuretic peptide(NT-proBNP) were significantly decreased in the 2 groups(P < 0.05), while the 6-keto-prostaglandin F1α(6-ketoPGF1α) level was significantly increased. And the changes in observation group were significantly greater than those in control group(P < 0.05). CONCLUSION: Tanshinone combined with western medicine can significantly improve the clinical symptoms of patients with acute heart failure, improve cardiac function, reduce the myocardial damage degree, and effectively reduce the risk of short-term recurrence and death, and it has exact clinical efficacy.

Effect of recombinant human brain natriuretic peptide on serum inflammatory factors, neuroendocrine hormones and cardiac function in patients with acute myocardial infarction complicated with heart failure

Objective:To investigate the effect of recombinant human brain natriuretic peptide (BNP) on inflammatory factors, neuroendocrine hormones and cardiac function indexes in patients with acute myocardial infarction complicated with heart failure.Methods:A total of91 cases of acute myocardial infarction with heart failure patients were divided into the control group (n=44) and observation group (n=47) according to the random data table, two groups of patients were given conventional treatment, based on this, the control group was given intravenous infusion of Nitroglycerin Injection treatment, the observation group received intravenous injection of recombinant human brain natriuretic peptide treatment, compared serum inflammatory factors, neuroendocrine hormone and cardiac function and other indexes of two groups before and after treatment.Results: there was no significant difference between the two groups before treatment. After treatment, the levels of TNF-α, hs-CRP, IL-6, MCP-1, LVESD and LVEDD in the two groups were significantly lower than those within the group before treatment, and the observation group was significantly lower than the control group;The two groups after treatment LVEF levels were significantly higher than those in the group before treatment, and the observation group was significantly higher than that of control group;the observation group after treatment PRA, Ang II and ALD and NE levels were significantly lower than those before treatment, and was significantly lower than the control group after treatment, the difference was significant, PRA, Ang, ALD and NE levels of control group before and after the treatment was no significant difference.Conclusion:recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction with heart failure can effectively reduce the serum inflammatory factors and neuroendocrine hormone levels, improve heart function, and have a certain clinical value.

Development of Nursing Protocol for Preventing Discontinuation of Treatments by Methods Other than Physical Restraint during Acute Exacerbation of Chronic Heart Failure in Patients with Impaired Cognitive Function

The purpose of this study is to prepare a nursing protocol for preventing discontinuation of treatments using a method other than physical restraint during acute exacerbation of chronic heart failure in patients with impaired cognitive function. For the first stage of the study, we prepared a draft of the nursing protocol based on a basic survey. For the second stage, semi-structured interviews were conducted with 5 nurses specialized in chronic heart failure and 10 nurses in dementia case to ensure content validity of the draft protocol. For the third stage, we examined the possibility of clinical application of the revised version of the protocol draft prepared in the second stage of the study. For assessment items, significant points of nursing care, and specific nursing care practice in this revised version, 154 subjects (93.9%) considered effective for patients, in terms of prevention of treatment discontinuation using a method other than physical restraint. All items and contents were considered useful by more than 60% of the nurses. Considering that the nurses working in the clinical setting reported 93.9% of usefulness, we concluded that this nursing protocol remained valid at a certain level. We also received a comment from the certified nurses that we should include the basic contents for newly graduated nurses. We consider that this nursing protocol will be also useful for newly graduated nurses to acquire knowledge. It helped to standardize nursing care in order to predict potential risks for patients with impaired cognitive function.

Application of non-invasive ventilator in the treatment of acute heart failure merged with respiratory failure in ICU

Objective:To observe the application effect of non-invasive ventilator in the treatment of acute heart failure merged with respiratory failure in ICU.Methods:A total of 80 patients with acute heart failure merged with respiratory failure who were admitted in ICU from January, 2015 to January, 2016 were included in the study and randomized into the observation group and the control group with 40 cases in each group. The patients in the two groups were given routine treatments after admission. On this basis, the patients in the observation group were given non-invasive ventilator. The patients in the control group were given continuous low flow oxygen inhalation. PaO2, pH, PaCO2, SaO2, and PaO2/FiO2 before and after treatment between the two groups were compared. The serum NT-pro BNP and cTnI levels before treatment, 24 h and 48 h after treatment in the two groups were compared.Results:The comparison of PaO2, pH, PaCO2, SaO2, and PaO2/FiO2 before treatment between the two groups was not statistically significant. PaO2, pH, SaO2, and PaO2/FiO2 after treatment in the two groups were significantly elevated, while PaCO2 was significantly reduced when compared with before treatment. PaO2, pH, SaO2, and PaO2/FiO2 after treatment in the observation group were significantly higher than those in the control group, while PaCO2 was significantly lower than that in the control group. The comparison of NT-pro BNP and cTnI levels before treatment between the two groups was not statistically significant. NT-pro BNP and cTnI levels 12 h and 24 h after treatment in the two groups were significantly elevated when compared with before treatment. NT-pro BNP and cTnI levels 12 h and 24 h after treatment in the observation group were significantly lower than those in the control group.Conclusions:Non-invasive ventilator in the treatment of acute heart failure merged with respiratory failure can effectively improve the ventilation function, reduce NT-pro BNP and cTnI levels, and is of great significance in enhancing the rescued effect.

Effects of low molecular weight heparin on the function of blood coagulation and serum levels of TNF-α, CK-MB, CRP of patients with acute exacerbations of chronic obstructive pulmonary diseases and respiratory failur

Objective:To study the effects of low molecular weight heparin on the function of blood coagulation and serum levels of tumor necrosis factor-α(TNF-α), creatine kinase isoenzyme (CK-MB), C-reactive protein (CRP) of patients with acute exacerbations of chronic obstructive pulmonary diseases and respiratory failure.Methods:A total of 80 patients with acute exacerbations of chronic obstructive pulmonary diseases and respiratory failure in our hospital from June 2014 to October 2016 were enrolled in this study. The subjects were divided into the control group (n=40) and the treatment group (n=40) randomly. The control group were treated with conventional treatment, the treatment group were treated with the conventional treatment combined with low molecular weight heparin. The two groups were treated for 7 d. The D-dimer (D-D), fibrinogen (FBG), pro thrombin time (PT), thrombin time (TT), TNF-α, CK-MB and CRP of the two groups before and after treatment were compared.Results:There were no significantly differences of the blood levels of D-D, FBG, PT and TT of the two groups before treatment. After treatment, the blood levels of D-D and FBG of the two groups were significantly lower than before treatment, and that of the treatment group were significantly lower than the control group, the PT and TT of the two groups were significantly higher than before treatment, and that of the treatment group were significantly higher than the control group. There were no significantly differences of the serum levels of the TNF-α, CK-MB and CRP of the two groups before treatment. After treatment, the serum levels of the TNF-α, CK-MB and CRP of the two groups were significantly lower than before treatment, and that of the treatment group were significantly lower than the control group.Conclusion:Low molecular weight heparin can significantly reduce the inflammatory factors of the patients with acute exacerbations of chronic obstructive pulmonary diseases and respiratory failure, can alleviath the patients conditions and reduce the myocardial damage.

Effect of sequential assist-control ventilation on cardio-pulmonary function and systemic inflammatory state of chronic pulmonary heart disease complicated with respiratory failure patients

Objective:To discuss the effect of sequential assist-control ventilation on cardio-pulmonary function and systemic inflammatory state of chronic pulmonary heart disease complicated with respiratory failure patients.Method: A total of 90 cases of chronic pulmonary heart disease complicated with respiratory failure patients, who were treated in our hospital between May, 2012 and Feb., 2016, were selected, and were divided into study group (n=45) and control group (n=45) based on random number table. Patients in control group were given auxiliary - control ventilation. (A/C) treatment during the whole course, while patients in study group were given A/C+BiPAP treatment. Cardio-pulmonary function and serum inflammatory factor content difference was compared inboth groups before and after operation.Results: Before treatment, difference ofcardiac function indicator, ABG level and inflammatory factor content in both groups had no statistical significance. After treatment, cardiac function indicator (PASP, RVd) levels in both groups were lower than before treatment, and EFRV levels were higher than before treatment, and changes in study group were more obvious than that in control group;ABG indicator (PaO2) levels in both groups were higher than before treatment, and PaCO2 levels werelower than before treatment, and changes in study group were more obvious than that in control group;serum inflammatory factor (hs-CRP, IL-6, TNF-α) content in both groups was lower than before treatment, and changes in study group were more obvious than that in control group.Conclusion: sequential assist-control ventilation could optimize the cardio-pulmonary function of chronic pulmonary heart disease complicated with respiratory failure patients and reduce the systemic inflammatory response.

Respiratory training interventions improve health status of heart failure patients: A systematic review and network meta-analysis of randomized controlled trials

BACKGROUND Prior studies indicate that doing breathing exercises improves physical performance and quality of life (QoL) in heart failure patients. However, these effects remain unclear and contradictory. AIM To determine the effects of machine-assisted and non-machine-assisted respiratory training on physical performance and QoL in heart failure patients. METHODS This was a systematic review and network meta-analysis study. A literature search of electronic databases was conducted for randomized controlled trials (RCTs) on heart failure. Respiratory training interventions were grouped as seven categories: IMT_Pn (inspiratory muscle training without pressure or < 10% maximal inspiratory pressure, MIP), IMT_Pl (inspiratory muscle training with low pressure, 10%-15% MIP), IMT_Pm (inspiratory muscle training with medium pressure, 30%-40% MIP), IMT_Ph (inspiratory muscle training with high pressure, 60% MIP or MIP plus aerobics), Aerobics (aerobic exercise or weight training), Qi_Ex (tai chi, yoga, and breathing exercise), and none. The four outcomes were heart rate, peak oxygen uptake (VO2 peak), 6-min walking distance test (6MWT), and Minnesota Living with Heart Failure QoL. The random-effects model, side-splitting model, and the surface under the cumulative ranking curve (SUCRA) were used to test and analyze the data. RESULTS A total of 1499 subjects from 31 RCT studies were included. IMT_Ph had the highest effect sizes for VO2 peak and 6MWT, IMT_Pm highest for QoL, and Qi_Ex highest for heart rate. Aerobics had the second highest for VO2 peak, Qi_Ex second highest for 6MWT, and IMT_Ph second highest for heart rate and QoL.CONCLUSION This study supports that high- and medium-intensity machine-assisted training improves exercise capacity and QoL in hospital-based heart failure patients. After hospital discharge, non-machine-assisted training continuously improves cardiac function.

HFNC治疗AECOPD合并呼吸衰竭的疗效及安全性研究

目的探讨经鼻高流量湿化氧疗(HFNC)治疗慢性阻塞性肺疾病急性加重期(AECOPD)合并呼吸衰竭的疗效及安全性。方法选择2021年1月至2023年1月新乡医学院第一附属医院收治的80例AECOPD合并呼吸衰竭患者进行研究,按随机数表法分为观察组和对照组各40例。对照组患者给予无创正压通气(NIPPV)治疗,观察组患者给予HFNC治疗,两组患者均连续治疗1周。比较两组患者的临床疗效及治疗前后的肺功能指标[第一秒最大呼气容积(FEV_(1))、FEV_(1)与用力肺活量比值(FEV_(1)/FVC)%、最大呼气流量(PEF)]、动脉血气指标[动脉氧分压(PaO_(2))、动脉二氧化碳(PaCO_(2))、血氧饱和度(SpO_(2))]、炎症因子[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)、白细胞介素-6(IL-6)]水平,并记录两组患者的并发症发生情况。结果观察组患者的治疗总有效率为95.00%,明显高于对照组的80.00%,差异有统计学意义(P<0.05);观察组患者治疗后的FEV_(1)、FEV_(1)/FVC、PEF水平分别为(1.85±0.36)L、(68.64±6.73)%、(3.80±1.04)L/s,明显高于对照组的(1.53±0.38)L、(62.48±6.24)%、(3.26±0.98)L/s,差异均具有统计学意义(P<0.05);观察组患者治疗后的PaO_(2)、SpO_(2)水平分别为(88.46±6.73)mmHg、(86.25±12.31)%,明显高于对照组的(82.33±7.94)mmHg、(78.37±13.62)%,PaCO_(2)水平为(34.30±8.51)mmHg,明显低于对照组的(40.62±6.44)mmHg,差异均具有统计学意义(P<0.05);观察组患者治疗后的CRP、TNF-α、IL-4、IL-6水平分别为(5.16±0.32)mg/L、(30.93±2.60)mg/L、(40.81±6.54)pg/L、(41.02±7.60)pg/L,明显低于对照组的(7.57±1.02)mg/L、(52.78±3.83)mg/L、(57.04±7.40)pg/L、(64.86±8.91)pg/L,差异均有统计学意义(P<0.05);治疗后,观察组患者的鼻舌干燥、腹胀、面部压伤的发生率分别为5.00%,2.50%,0,明显低于对照组的22.50%,17.50%,12.50%,差异均有统计学意义(P<0.05),而两组患者的低血压发生率比较差异无统计学意义(P>0.05)。结论HFNC治疗AECOPD合并呼吸衰竭能提高患者的肺功能,改善动脉血气指标,降低炎症指标和并发症的发生率,临床应用效果显著。

参附注射液治疗心肾阳虚型慢性心力衰竭急性加重的临床研究

目的:观察参附注射液治疗心肾阳虚型慢性心力衰竭急性加重的临床疗效。方法:选取2023年10月—2024年1月在安徽中医药大学第一附属医院住院的慢性心力衰竭急性加重病人60例,按照随机数字表法分为观察组与对照组,各30例。观察组给予参附注射液加西医常规治疗,对照组仅给予西医常规治疗,比较两组治疗前后血浆氨基末端B型钠尿肽前体(NT-proBNP)、超敏肌钙蛋白I(hs-cTnI)、6 min步行试验(6MWT)、明尼苏达州心力衰竭生活质量问卷评分(MLHFQ)、中医证候积分及纽约心脏病协会(NYHA)心功能分级。结果:与治疗前比较,两组治疗后NT-proBNP、hs-cTnI水平降低(P<0.05),两组治疗后NT-proBNP、hs-cTnI水平比较差异均无统计学意义(P>0.05);与治疗前比较,两组治疗后6MWT、MLHFQ评分均明显改善(P<0.05),观察组改善程度优于对照组(P<0.05);两组治疗后各单项中医证候积分低于治疗前(P<0.05),观察组治疗后喘促气短、倦怠乏力、畏寒肢冷及言语声低评分低于对照组(P<0.05)。观察组总有效率为96.7%,对照组为80.0%,两组比较差异有统计学意义(P<0.05)。结论:参附注射液联合西药常规治疗可改善心肾阳虚型慢性心力衰竭急性加重病人心功能,提高病人运动耐量和生活质量。

参附注射液对急性心衰患者炎性指标、心功能及临床疗效的影响

目的观察参附注射液对急性心力衰竭(心肾阳虚型)患者的疗效,并探讨其作用机制。方法89例患者按随机数字表法分为观察组45例与对照组44例,两组均给予常规西药治疗,观察组在对照组基础上加用参附注射液。比较两组血清炎性指标、血流动力学指标、心功能及临床疗效。结果两组治疗前白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、左心室射血分数(LVEF)、脑利钠肽(BNP)、肌酸激酶同工酶(CK-MB)、肌钙蛋白T(cTnT)水平和血流动力学指标心排血量(CO)、平均动脉压(MAP)、肺动脉压(PAP)水平比较,差异无统计学意义(均P>0.05)。两组治疗后5、10 d,IL-6、hs-CRP、LVEF、BNP、CK-MB、cTnT水平和血流动力学指标CO、MAP、PAP水平均较治疗前改善(均P<0.05),且观察组的各项指标改善均优于对照组(P<0.05)。治疗后观察组的总有效率为86.67%,高于对照组的72.73%。两组治疗期间及治疗后均未发现不良反应。结论参附注射液治疗急性心力衰竭可有效降低患者的血清炎性指标,改善血流动力学,提高心功能,改善生活质量,疗效良好。

机械通气对ICU重症心力衰竭患者呼吸循环及心功能的影响

目的探讨机械通气在重症监护室(ICU)重症心力衰竭临床治疗中的应用效果,结合患者的呼吸循环及心功能恢复情况进行评价。方法选取我院2020年2月至2023年6月收治的ICU重症心力衰竭患者84例作为研究对象,随机分为观察组(机械通气+常规治疗)和对照组(常规治疗)各42例,对比两组患者的呼吸循环功能、心功能及并发症发生情况。结果治疗后,观察组呼吸频率、PaCO_(2)低于对照组,氧合指数、PaO_(2)高于对照组(P<0.05)。观察组LVEF高于对照组,LVESV、LVEDV、NT-proBNP、CK-MB低于对照组(P<0.05)。观察组并发症发生率低于对照组(4.8%vs.21.4%,P=0.024)。结论在ICU重症心力衰竭患者的临床治疗中,实施机械通气治疗,在改善呼吸循环、促进心功能恢复等方面具有良好的效果。

重组人脑利钠肽对急性失代偿性心力衰竭的疗效及相关指标的影响探讨

目的观察重组人脑利钠肽(rhBNP)对急性失代偿性心力衰竭的疗效及相关指标的影响。方法78例急性失代偿性心力衰竭患者,根据治疗方案差异分成对照组与观察组,每组39例。对照组采取常规治疗,观察组在对照组基础上加用重组人脑利钠肽治疗。比较两组治疗前后临床症状评分、炎性介质水平、血管内皮功能、心功能指标及生存质量。结果治疗后,两组呼吸困难、下肢水肿、入睡困难、喘息不止、颈静脉怒张评分较治疗前更低,且观察组呼吸困难、下肢水肿、入睡困难、喘息不止、颈静脉怒张评分分别为(1.05±0.26)、(1.43±0.25)、(0.77±0.21)、(1.51±0.45)、(1.29±0.62)分,较对照组的(2.52±0.89)、(2.31±0.67)、(1.07±0.38)、(2.12±0.36)、(2.31±0.72)分更低(P<0.05)。治疗后,两组肿瘤坏死因子-α、白细胞介素-6、超敏C反应蛋白水平较治疗前更低,且观察组肿瘤坏死因子-α、白细胞介素-6、超敏C反应蛋白水平分别为(0.43±0.15)pg/L、(8.86±1.51)pg/ml、(8.10±1.15)mg/L,较对照组的(0.61±0.11)pg/L、(10.51±1.62)pg/ml、(10.32±1.22)mg/L更低(P<0.05)。治疗后,两组一氧化氮、内皮素-1水平较治疗前更低,且观察组一氧化氮水平(53.81±7.92)μmol/L、内皮素-1水平(40.91±2.30)ng/L较对照组的(60.46±6.42)μmol/L、(52.16±3.63)ng/L更低(P<0.05)。两组治疗后左心室射血分数、心输出量、心脏指数较治疗前更高,左心室舒张末期内径、左心室收缩末期内径较治疗前更小,且观察组左心室射血分数、心输出量、心脏指数较对照组更高,左心室舒张末期内径、左心室收缩末期内径较对照组更小(P<0.05)。两组治疗后生理、心理、社会关系、环境评分较治疗前更高,且观察组较对照组更高(P<0.05)。结论采用重组人脑利钠肽治疗急性失代偿性心力衰竭效果显著,其能够改善患者临床相关症状及血管内皮功能,有助于心功能早日恢复至健康状态。

有创机械通气对ICU重症心力衰竭患者呼吸循环功能及心功能的影响

目的:探讨有创机械通气在ICU重症心力衰竭(HF)患者中的应用效果。方法:选取2020年6月—2022年6月河南省永城市人民医院收治的86例重症HF患者作为研究对象,采用随机数表法分为对照组和观察组,每组各43例。对照组患者给予常规药物治疗,观察组患者在对照组的基础上加用有创机械通气治疗,均于治疗7 d后进行评价。比较两组患者呼吸循环功能、神经内分泌因子水平、心功能及不良心血管事件情况。结果:治疗后,观察组患者动脉血氧分压(PaO_(2))、氧合指数(OI)高于对照组,二氧化碳分压(PaCO_(2))、呼吸频率(RR)较对照组低,差异有统计学意义(t=3.685、5.912、5.854、4.972,P<0.05);治疗后,观察组患者醛固酮(ALD)、心房钠尿肽(ANP)水平低于对照组,皮质醇(COR)高于对照组,差异有统计学意义(t=5.303、4.590、4.418,P<0.05);治疗后,观察组患者左室射血分数(LVEF)高于对照组,左室收缩末内径(LVESD)、左室舒张末内径(LVEDD)、血管阻力(SVR)低于对照组,差异有统计学意义(t=5.384、6.772、6.272、4.439,P<0.05);观察组患者不良心血管事件较对照组少,差异有统计学意义(χ^(2)=4.441,P<0.05)。结论:有创机械通气可改善ICU重症HF患者呼吸循环功能,纠正神经内分泌因子紊乱,加快心功能恢复,减少不良心血管事件发生。

分析便携式呼吸睡眠监测联合集束化护理干预改善心力衰竭患者睡眠情况的效果

目的:分析便携式呼吸睡眠监测联合集束化护理干预改善心力衰竭患者睡眠情况的效果。方法:选取2022年1月至2023年6月厦门大学附属第一医院收治的心力衰竭患者86例作为研究对象,按照随机数字表法分为对照组和观察组,每组43例。对照组给予集束化护理干预,观察组给予便携式呼吸睡眠监测干预。利用便携式呼吸睡眠监测仪检测2组的入睡潜伏期、觉醒次数、觉醒时间及实际睡眠时间,采用理查兹-坎贝尔睡眠量表(RCSQ)评估包括睡眠状态、夜间觉醒、重回入睡、睡眠深度的变化,采用彩色多普勒超声仪检测患者的左室射血分数,采用标准参照康纳-戴维森韧性量表(CD-RISC)评估2组患者干预前后心理弹性水平的变化。结果:干预后,观察组入睡潜伏期、觉醒时间及觉醒次数显著低于对照组,实际睡眠时间显著高于对照组,差异均有统计学意义(均P<0.05);观察组的睡眠状态及睡眠深度评分显著高于对照组,观察组夜间觉醒、重回入睡评分显著低于对照组,差异均有统计学意义(均P<0.05);干预后,观察组的左室射血分数与心理弹性CD-RISC评分均高于对照组,差异均有统计学意义(均P<0.05)。结论:便携式呼吸睡眠监测联合集束化护理有利于改善心力衰竭患者的睡眠情况,提升睡眠质量,加快心功能的恢复,临床可进一步推广应用。

经鼻高流量氧疗对比无创正压通气在急性心力衰竭伴Ⅰ型呼吸衰竭患者中的应用价值

目的研究经鼻高流量氧疗(high flow nasal cannula oxygen therapy,HFNC)对比无创正压通气(noninvasive positive pressure ventilation,NPPV)在急性心力衰竭(acute heart failure,AHF)伴Ⅰ型呼吸衰竭患者的治疗效果。方法选择2022年1月至2022年12月首都医科大学宣武医院急诊科收治的94例AHF伴Ⅰ型呼吸衰竭患者,随机分为观察组48例和对照组46例。两组患者均给予常规扩血管、利尿等治疗,对照组给予NPPV治疗,观察组给予HFNC治疗,分别比较两组患者治疗前、治疗24 h后的呼吸频率、心率、血清N末端B型利钠肽原(NT-proBNP)、动脉氧分压(PaO_(2))和动脉二氧化碳分压(PaCO_(2))的变化情况及2组比较的区别,应用调查问卷评估两组患者治疗舒适度的区别。随访28 d,分别比较两组患者治疗后误吸、胃胀气等并发症发生率、气管插管率及病死率。结果观察组与对照组治疗后的呼吸频率、心率和NT-proBNP较前明显降低(P均<0.05),PaO_(2)较前升高(P均<0.05),PaCO_(2)较前升高(P<0.05),但仍在正常范围内;观察组治疗后呼吸频率是(23.77±2.36)次/min、心率为(89.17±5.80)次/min、NT-proBNP为[13631.00(9997.25,16328.00)]pg/ml、PaO_(2)为(66.87±2.78)mmHg和PaCO_(2)为(37.06±2.56)mmHg,与对照组的(23.33±2.81)次/min、(87.69±5.02)次/min、[12517.00(9836.75,17742.00)]pg/ml、(67.74±2.67)mmHg和(37.07±1.93)mm Hg比较无统计学差别(均P>0.05);调查问卷显示,观察组舒适度评分大于对照组[(3.35±0.69)分比(2.76±0.77)分,P=0.001],并发症发生率小于对照组(10.41%比28.26%,P=0.028),两组患者气管插管率(12.50%比10.86%)和病死率(10.41%比8.69%)比较无统计学差别(P>0.05)。结论HFNC和NPPV在AHF伴Ⅰ型呼吸衰竭患者中应用均具有较好的治疗效果,但HFNC并发症较较少,患者舒适程度更高。

注射用重组人脑利钠肽对急性心力衰竭患者心功能指标、再入院率及炎症因子的影响

目的探讨注射用重组人脑利钠肽对急性心力衰竭心功能指标、再入院率及炎症因子的影响。方法收集郑州大学第五附属医院2021年7月至2022年7月收治的90例急性心力衰竭患者进行研究,按随机数字表法分为两组。对照组45例接受吸氧、洛尔类药物、利尿药物、普利类药物、低盐饮食、强心剂等治疗。观察组45例在前基础上加注射用重组人脑利钠肽治疗。观察两组疗效、心功能指标[左室射血分数(LVEF)、心脏指数(CI)、心排血量(CO)]、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、N端B型钠尿肽前体(NT-proBNP)、转化生长因子-β1(TGF-β1)水平、再入院率、心率、不良反应发生率。结果观察组总有效率高于对照组(P<0.05)。干预后两组心功能指标(LVEF、CI、CO)水平提高,观察组高于对照组(P<0.05)。干预后两组IL-6、TGF-β1、NT-proBNP、hs-CRP、TNF-α水平降低,观察组低于对照组(P<0.05)。观察组再入院率、心率低于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论注射用重组人脑利钠肽可改善急性心力衰竭患者的心功能,减轻炎症反应,并且能降低患者再入院率。

慢性心力衰竭患者血清TFAM、PGC-1α、NRF-1水平与心功能的相关性

目的探究慢性心力衰竭(CHF)患者血清线粒体转录因子A(TFAM)、过氧化物酶体增殖物激活受体γ共激活因子1α(PGC-1α)、核呼吸因子1(NRF-1)水平与心功能的相关性。方法选取2022年1月至2023年1月于哈尔滨市第一医院经检查确诊的105例CHF患者作为CHF组,根据纽约心脏病协会(NYHA)心功能分级将CHF组患者分为Ⅰ~Ⅱ级42例、Ⅲ级35例、Ⅳ级28例;选取同期于本院体检的健康检查者105例为对照组,比较两组及CHF组不同心功能分级血清TFAM、PGC-1α、NRF-1水平以及心功能指标。Pearson法分析CHF组患者血清TFAM、PGC-1α、NRF-1水平与心功能指标的关系。结果CHF组患者血清TFAM、PGC-1α、NRF-1水平低于对照组(P<0.05)。CHF组患者左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)水平高于对照组,左室射血分数(LVEF)水平低于对照组(P<0.05)。随着心功能分级(NYHAⅠ~Ⅱ级、Ⅲ级和Ⅳ级)逐渐升高,CHF组患者血清TFAM、PGC-1α、NRF-1水平逐渐降低(P<0.05);LVEDD、LVESD水平逐渐升高,LVEF水平逐渐降低(P<0.05)。相关性分析显示,LVEF与血清TFAM、PGC-1α、NRF-1水平呈正相关(r=0.474、r=0.461、r=0.513,P<0.05);LVEDD与血清TFAM、PGC-1α、NRF-1水平呈负相关(r=-0.511、r=-0.502、r=-0.475,P<0.05);LVESD与血清TFAM、PGC-1α、NRF-1水平呈负相关(r=-0.497、r=-0.515、r=-0.462,P<0.05)。结论CHF患者血清TFAM、PGC-1α、NRF-1水平降低,且三者与心功能指标密切相关。

Gal-3、Hcy和甲状腺功能水平与急性心肌梗死患者心力衰竭程度及预后的相关性

目的 探究血清半乳凝素-3(Gal-3)、同型半胱氨酸(Hcy)和甲状腺功能水平与急性心肌梗死患者心力衰竭程度及预后的相关性。方法 回顾性选取2018年4月至2020年4月在秦皇岛市第一医院接受治疗的100例急性心肌梗死患者,根据患者是否发生心力衰竭将患者分组:56例患者未发生心力衰竭,纳入对照组,其他44例发生心力衰竭的患者纳入观察组。比较2组患者的血清Gal-3、Hcy和游离三碘甲腺原氨酸(FT_(3))、游离甲状腺素(FT_(4))、促甲状腺激素(TSH)水平;根据Killip分级将观察组患者分为轻度组(n=16)、中度组(n=19)、重度组(n=9),比较3组患者的Gal-3、Hcy、FT_(3)、FT_(4)、TSH水平;对观察组患者进行1年随访,根据患者随访期内是否发生主要心血管不良事件(MACE)将患者分为预后良好组(n=28)和预后不良组(n=16),比较2组患者的Gal-3、Hcy、FT_(3)、FT_(4)、TSH水平。采用受试者操作特征(ROC)曲线分析Gal-3、Hcy、FT_(3)、FT_(4)、TSH水平对患者预后的预测价值。结果 观察组患者的Gal-3、Hcy、TSH水平分别为(13.33±3.87)μg/L、(19.11±3.16)μmol/L、(8.49±2.46) mIU/L,均高于对照组[(9.98±3.12)μg/L、(16.56±3.05)μmol/L、(6.45±2.04) mIU/L],FT_(3)、FT_(4)水平分别为(1.25±0.56)、(6.45±1.78) pmol/L,均低于对照组[(1.55±0.31)、(7.56±1.25) pmol/L],差异均有统计学意义(P<0.05)。不同程度心力衰竭患者组间Gal-3、Hcy、FT_(3)、FT_(4)、TSH水平比较,差异均有统计学意义(P<0.05),随着病情严重程度越重,Gal-3、Hcy、TSH水平越高,FT_(3)、FT_(4)水平越低。预后不良组患者的Gal-3、Hcy、TSH水平均高于预后良好组,FT_(3)、FT_(4)水平均低于预后良好组,差异均有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,患者血清Gal-3、Hcy、FT_(3)、FT_(4)、TSH水平均是患者预后的影响因素(P<0.05)。Gal-3、Hcy、FT_(3)、FT_(4)、TSH水平预测患者预后不良的曲线下面积分别为0.985、0.877、0.942、0.916、0.969。结论 Gal-3、Hcy和甲状腺功能水平与急性心肌梗死患者心力衰竭程度及预后存在相关性,可以作为评估急性心肌梗死患者心力衰竭严重程度和预测预后的重要指标。

改良动态ROX指数对急性呼吸衰竭患者HFNC治疗失败的预测价值

目的 分析改良动态ROX指数对急性呼吸衰竭患者高流量鼻导管(HFNC)治疗失败的预测价值。方法 选取2021年3月至2023年3月的急性呼吸衰竭患者102例,HFNC成功66例,失败36例,改良ROX指数为PaO_(2)/FIO_(2)与RR×HR的比值×100,动态指数定义为HFNC前与HFNC 2 h指数的差值,分析不同指数对HFNC失败的预测效能及相关因素。结果 HFNC失败组年龄、APACHE II评分高于HFNC成功组。HFNC 2 h时,HFNC成功组HR、RR和FiO_(2)低于HFNC失败组,SpO_(2)、PaO_(2)、PaCO_(2)、SpO_(2)/FIO_(2)和PaO_(2)/FIO_(2)高于HFNC失败组。HFNC成功组HFNC持续时间、HFNC 2 h ROX,动态ROX,HFNC 2 h改良ROX和改良动态ROX指数均高于HFNC失败组。动态ROX、HFNC 2 h改良ROX和改良动态ROX的AUC(95%CI)分别为0.703(0.590~0.790)、0.726(0.622~0.829)和0.811(0.717~0.902),临界值分别为0.97、6.78和0.12。对混杂因素进行调整后,动态ROX>0.97、HFNC 2 h改良ROX>6.78和改良动态ROX>0.12是HFNC失败风险降低的影响因素。结论 改良动态ROX指数可早期预测HFNC预后,改良动态ROX>0.12和HFNC 2 h改良ROX>6.78在预测急性呼吸衰竭患者HFNC失败风险方面表现良好。

经鼻高流量湿化氧疗治疗急性心力衰竭合并呼吸衰竭患者的临床疗效研究

目的 探讨在急性心力衰竭(AHF)合并呼吸衰竭患者的治疗中实施经鼻高流量湿化氧疗(HFNC)干预的临床效果。方法 78例急性心力衰竭合并呼吸衰竭患者,随机分为对照组和观察组,每组39例。对照组患者在常规治疗的基础上实施低流量氧疗,观察组患者在常规治疗的基础上联合实施经鼻高流量湿化氧疗。对比两组患者治疗后1、24 h的有效率、血气指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))],治疗前后心率、呼吸频率与血清C反应蛋白(CRP)、B型脑钠肽(BNP)水平,气管插管率与1个月内死亡率。结果 观察组治疗后1、24 h的有效率分别为79.49%、97.44%,均高于对照组的51.28%、79.49%(P<0.05)。治疗后1、24 h,观察组患者的心率、呼吸频率分别为(105.47±3.36)、(23.42±2.36)次/min和(91.31±2.54)、(19.45±2.86)次/min,均低于对照组的(116.72±3.52)、(27.58±3.52)次/min和(96.30±3.52)、(22.61±4.01)次/min(P<0.05)。治疗后1、24 h,观察组患者的PaO_(2)分别为(89.94±1.54)、(93.94±2.70)mm Hg(1 mm Hg=0.133 kPa),均高于对照组的(84.19±2.27)、(89.86±1.53)mm Hg, PaCO_(2)分别为(40.84±4.32)、(35.84±2.37)mm Hg,均低于对照组的(45.84±3.56)、(44.62±1.38)mm Hg(P<0.05)。治疗后24 h,观察组患者血清CRP(28.42±4.52)mg/L、BNP(2342.92±24.59)pg/ml均低于对照组的(35.98±5.27)mg/L、(3876.65±34.19)pg/ml(P<0.05)。观察组气管插管率5.13%低于对照组的20.51%(P<0.05);两组1个月死亡率对比,差异无统计学意义(P>0.05)。结论 对于急性心力衰竭合并呼吸衰竭患者早期采用经鼻高流量湿化氧疗效果显著,可以降低患者气管插管率,改善患者心力衰竭症状,提高治疗效果。